

# Luigi Boiardi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11838883/publications.pdf>

Version: 2024-02-01

79  
papers

5,250  
citations

81839

39  
h-index

85498

71  
g-index

81  
all docs

81  
docs citations

81  
times ranked

2978  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of TNF- $\hat{I}$ antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	0.9	26
2	Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study. <i>RMD Open</i> , 2022, 8, e001977.	1.8	7
3	Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 402-408.	1.5	18
4	Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. <i>Rheumatology</i> , 2021, 60, 3851-3861.	0.9	38
5	Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 786-792.	1.6	16
6	Response to "The Relevance of Restricted Inflammation in a TAB" by Griffin KJ et al. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, e8-e9.	1.6	1
7	Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 549-558.	1.6	29
8	Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 986.2-988.	0.5	49
9	Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1064-1072.	1.6	22
10	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 98, 113-121.	3.0	7
11	Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1074-1082.	1.6	40
12	Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study. <i>Rheumatology</i> , 2019, 58, 609-616.	0.9	26
13	Increased expression of interleukin-22 in patients with giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 64-72.	0.9	20
14	Unmet Needs in the Pathogenesis and Treatment of Vasculitides. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 244-260.	2.9	21
15	Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings. <i>Arthritis Care and Research</i> , 2017, 69, 143-149.	1.5	64
16	Incidence, Prevalence, and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy During a 26-Year Period. <i>Arthritis Care and Research</i> , 2017, 69, 430-438.	1.5	55
17	No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 235-240.	1.6	35
18	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78

#	ARTICLE	IF	CITATIONS
19	Visual loss and other cranial ischaemic complications in giant cell arteritis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 476-484.	3.5	121
20	Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study. <i>Journal of Autoimmunity</i> , 2017, 77, 39-44.	3.0	27
21	Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy. <i>Medicine (United States)</i> , 2016, 95, e3524.	0.4	78
22	Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2016, 68, 865-870.	1.5	26
23	Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016, 69, 94-101.	3.0	33
24	MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1527-1533.	0.5	37
25	Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. <i>Rheumatology</i> , 2015, 54, 1596-1604.	0.9	66
26	Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study. <i>Rheumatology</i> , 2015, 54, 400-404.	0.9	58
27	Inflamed Temporal Artery. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1360-1370.	2.1	147
28	Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1190-1193.	0.5	81
29	Brief Report: Interleukin-6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2469-2475.	6.7	51
30	Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 113-118.	1.6	59
31	IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 258-264.	0.5	55
32	Comparison between colour duplex sonography findings and different histological patterns of temporal artery. <i>Rheumatology</i> , 2013, 52, 2268-2274.	0.9	48
33	NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1852-1859.	0.5	44
34	CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. <i>Modern Rheumatology</i> , 2013, 23, 851-855.	0.9	3
35	TLR-4 and VEGF Polymorphisms in Chronic Periaortitis. <i>PLoS ONE</i> , 2013, 8, e62330.	1.1	8
36	CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. <i>Modern Rheumatology</i> , 2013, 23, 851-855.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Tocilizumab: a novel therapy for patients with large-vessel vasculitis. <i>Rheumatology</i> , 2012, 51, 151-156.	0.9	203
38	Adalimumab in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 77-81.	2.2	10
39	Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 549-556.	6.7	69
40	Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 776-8.	0.4	22
41	New indications for biological therapies. <i>Internal and Emergency Medicine</i> , 2011, 6, 1-9.	1.0	7
42	Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2097-2104.	6.7	31
43	Differential effects of anti-TNF- $\alpha$ drugs on fibroblast-like synoviocyte apoptosis. <i>Rheumatology</i> , 2010, 49, 480-489.	0.9	34
44	Multidisciplinary Focus on Cyclosporin A. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 52-55.	2.2	5
45	Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. <i>Rheumatology</i> , 2009, 48, 1566-1569.	0.9	55
46	Serum interleukin-6 receptor in polymyalgia rheumatica: A potential marker of relapse/recurrence risk. <i>Arthritis and Rheumatism</i> , 2008, 59, 1147-1154.	6.7	23
47	Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 577-579.	0.5	13
48	Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 2007, 146, 631.	2.0	158
49	PLA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3502-3508.	6.7	18
50	Treatment of refractory polymyalgia rheumatica with etanercept: An open pilot study. <i>Arthritis and Rheumatism</i> , 2007, 57, 1514-1519.	6.7	52
51	Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. <i>Journal of Rheumatology</i> , 2006, 33, 703-8.	1.0	58
52	Tumor necrosis factor-alpha protects synovial cells from nitric oxide induced apoptosis through phosphoinositide 3-kinase Akt signal transduction. <i>Journal of Rheumatology</i> , 2006, 33, 1061-8.	1.0	24
53	Are steroids alone sufficient for the treatment of giant cell arteritis?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 277-292.	1.4	25
54	Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective followup study. <i>Arthritis and Rheumatism</i> , 2005, 53, 33-38.	6.7	136

#	ARTICLE	IF	CITATIONS
55	Positron emission tomography (PET): Evaluation of chronic periaortitis. <i>Arthritis and Rheumatism</i> , 2005, 53, 298-303.	6.7	128
56	Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 293-297.	6.7	218
57	Are polymyalgia rheumatica and giant cell arteritis the same disease?. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 294-301.	1.6	130
58	Polymyalgia rheumatica. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 705-722.	1.4	80
59	Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. <i>Journal of Rheumatology</i> , 2004, 31, 120-4.	1.0	24
60	Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in southern europe. <i>Journal of Rheumatology</i> , 2004, 31, 520-3.	1.0	10
61	Vascular endothelial growth factor gene polymorphisms in Behçet's disease. <i>Journal of Rheumatology</i> , 2004, 31, 1785-9.	1.0	62
62	Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 3219-3223.	6.7	35
63	Cardiac Involvement in Systemic Vasculitis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, 1, 227-254.	0.1	0
64	Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. <i>Journal of Rheumatology</i> , 2003, 30, 760-3.	1.0	50
65	Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. <i>Journal of Rheumatology</i> , 2003, 30, 2160-4.	1.0	50
66	Is Duplex Ultrasonography Useful for the Diagnosis of Giant-Cell Arteritis?. <i>Annals of Internal Medicine</i> , 2002, 137, 232.	2.0	169
67	Polymyalgia Rheumatica and Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2002, 347, 261-271.	13.9	1,002
68	Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: A case-control study. <i>Arthritis and Rheumatism</i> , 2002, 46, 3099-3101.	6.7	45
69	Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. <i>Journal of Rheumatology</i> , 2002, 29, 535-40.	1.0	39
70	Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. <i>Arthritis and Rheumatism</i> , 2001, 44, 1155-1159.	6.7	47
71	Vascular endothelial growth factor production in polymyalgia rheumatica. <i>Arthritis and Rheumatism</i> , 2000, 43, 2472-2480.	6.7	32
72	Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2000, 30, 17-24.	1.6	178

#	ARTICLE	IF	CITATIONS
73	HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 303-308.	0.5	44
74	Distal musculoskeletal manifestations in polymyalgia rheumatica: A prospective followup study. <i>Arthritis and Rheumatism</i> , 1998, 41, 1221-1226.	6.7	141
75	Polymyalgia rheumatica. <i>Lancet, The</i> , 1997, 350, 43-47.	6.3	64
76	Therapy with cyclosporine in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1997, 27, 36-43.	1.6	35
77	Polymyalgia rheumatica. <i>Lancet, The</i> , 1996, 348, 550-551.	6.3	20
78	Giant cell arteritis in Mediterranean countries: Comment on the article by Salvarani et al. <i>Arthritis and Rheumatism</i> , 1992, 35, 1249-1250.	6.7	9
79	Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. <i>Arthritis and Rheumatism</i> , 1991, 34, 351-356.	6.7	198